Introduction

Across the UK in 2026, shoppers and retailers are encountering a new generation of CBD products that prominently feature CBG and CBN alongside CBD. This shift follows tighter controls on semi‑synthetic cannabinoids in 2025–26 and a growing appetite for multi‑cannabinoid formulas. The change brings opportunity — and fresh compliance and transparency challenges. Below we outline what’s trending, why it matters for consumers and retailers, clear examples from the market, and a forward‑looking checklist to help you judge authenticity and safety.

What’s trending

Several converging signals explain the surge in CBG‑ and CBN‑infused products:

• Independent testing reveals more than CBD in many OTC products. A UK analysis found that roughly 10% of total cannabinoid content in tested OTC CBD products was non‑CBD, with CBG measured as the most abundant non‑CBD cannabinoid (mean ~0.05%).
• Regulatory push‑back on semi‑synthetics. Tighter controls on semi‑synthetic cannabinoids such as HHC in 2025–26 have pushed both retailers and consumers towards naturally occurring cannabinoids like CBG and CBN, stimulating a wave of new product launches advertising multi‑cannabinoid formulas.
• Compliance concerns remain acute. Alarmingly, around 55% of products in a UK study had measurable THC or CBN and would be technically illegal under the UK’s zero‑tolerance for controlled cannabinoids — a clear market‑wide compliance risk.
• Transparency is becoming a selling point. Reputable brands now publish batch‑matched third‑party Certificates of Analysis (COAs) via QR codes or URLs on product pages and labels, and many highlight 0% THC or restricted‑cannabinoid‑free formulations as a compliance selling point.

Why this matters

The increased visibility of CBG and CBN matters for three practical reasons:

• Legal risk and product safety. Measurable amounts of THC or CBN can render a product unlawful in the UK. Consumers and retailers both face reputational and legal exposure if products are not properly tested and labelled.
• Trust and traceability. With varied manufacturing practices and white‑labelling across the industry, batch‑specific COAs and clear labelling are fast becoming a minimum expectation for trustworthy brands.
• Informed purchasing. CBN can sometimes indicate prior THC presence due to oxidative conversion; spotting CBN claims without clear COA context should prompt closer scrutiny.

Market examples

To give these trends some practical context, look for how different categories are responding:

• Dropper oils: many oil‑based tinctures now list multiple cannabinoids on the label and link to COAs. A traditional oil presentation such as the Wylde Natural Cold‑Pressed Drops 1000mg CBD Oil typifies the format where batch info and COA access are most expected.
• Gummies and edibles: full‑spectrum gummies will often contain trace cannabinoids — if you see a product like Wylde CBD Gummy Bears (full‑spectrum), check the COA for mg CBD per serving and the CBG/CBN numbers cited.
• Vapes and inhalables: following controls on HHC, many vape companies have repositioned existing products or relaunched formulas — examples include Canavape Blue Dream e‑liquid and the Blue Cheese Canavape cartridge — forms where scrutiny over controlled cannabinoids has intensified.
• High‑strength & THC‑free claims: some manufacturers now advertise restricted‑cannabinoid‑free formulas to reassure shoppers; an example at the high‑strength end is the CBD Living 4500mg 0% THC tincture, which markets a THC‑free profile as a compliance feature.

How consumers can spot authentic multi‑cannabinoid launches

When you’re evaluating a new CBG/CBN‑infused product, use this practical checklist:

• Batch‑matched COA accessible via QR/URL. The COA should explicitly match the product’s batch/lot number printed on the label. If there’s no batch number or no COA, treat it as a red flag.
• Clear cannabinoid declaration. COAs should show mg CBD per container and mg per serving, plus measured CBG and CBN levels and THC. Brands should declare spectrum type (full, broad, isolate) on the label.
• Practical THC benchmark. While UK law is zero‑tolerance, a practical retail benchmark commonly used by compliant brands is THC ≤1 mg per container. Anything above should prompt further investigation and legal caution.
• Lab reputation and accreditation. Look for ISO 17025 accreditation or a well‑known independent laboratory. COAs should include test dates, methods and ideally a chromatogram image.
• Watch for CBN context. CBN can indicate oxidative breakdown of THC. If a COA shows significant CBN without a clear explanation, ask the brand for manufacturing and storage details.
• Beware vague language. Phrases like “proprietary blend” or no explicit mg figures for cannabinoids are warning signs.
• Avoid exaggerated claims. Trusted brands avoid medical language; any product promising cures or treatments should be treated with scepticism.

Future outlook

Looking ahead, expect three defining movements:

• Greater transparency as standard. Batch‑matched COAs and visible lab credentials will increasingly separate reputable brands from the rest.
• Label standardisation. Pressure from regulators, retailers and consumer groups should push clearer mg‑per‑serving labelling and standard spectrum declarations.
• Formulation innovation within compliance limits. Brands and white‑label partners will continue refining multi‑cannabinoid profiles while navigating Novel Foods and FSA validation — and many will market THC‑free or restricted‑cannabinoid‑free options to reassure risk‑averse buyers.

Conclusion

The 2026 surge in CBG and CBN‑infused CBD products in the UK reflects both consumer curiosity and industry adaptation after regulatory shifts. This presents exciting product variety, but also underlines the need for careful scrutiny. Insist on batch‑matched third‑party COAs, clear mg‑per‑serving declarations, visible batch numbers and reputable lab accreditation. Those simple checks will help you separate authentic, compliant launches from offerings that carry legal and quality risks — and will make informed, confident choices easier in a rapidly evolving market.